Computer-Designed Proteins Programmed to Deactivate Flu Viruses
|
By LabMedica International staff writers Posted on 20 Jun 2012 |
Computer-designed proteins are now being constructed to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a range of flu virus strains, including H1N1 pandemic influenza.
“One of these engineered proteins has a flu-fighting potency that rivals that of several human monoclonal antibodies,” said Dr. David Baker, a professor of biochemistry at the University of Washington (Seattle, USA), in a report June 7, 2012, published in the journal Nature Biotechnology.
Dr. Baker’s research team is making major inroads in optimizing the function of computer-designed influenza inhibitors. These proteins are constructed via computer modeling to fit exquisitely into a specific nano-sized target on flu viruses. By binding the target areas similar to a key into a lock, they keep the virus from changing shape, a tactic that the virus uses to infect living cells. The research efforts, analogous to docking a space station but on a molecular level, are made possible by computers that can describe the panoramas of forces involved on the submicroscopic scale.
Dr. Baker is head of the new Institute for Protein Design Center at the University of Washington. Biochemists, engineers, computer scientists, and medical specialists at the center are engineering innovative proteins with new functions for specific purposes in medicine, environmental protection, and other areas. Proteins underlie all typical activities and structures of living cells, and also control disease actions of pathogens such as viruses. Abnormal protein formation and interactions are also implicated in many inherited and later-life chronic disorders.
Because influenza is a serious worldwide public health problem due to its genetic shifts and drifts that sporadically become more virulent, the flu is one of the key interests of the Institutes for Protein Design and its collaborators in the United States and worldwide. Researchers are trying to meet the vital need for better therapeutic agents to protect against this very adaptable and extremely infective virus. Vaccines for new strains of influenza take months to develop, evaluate, and manufacture, and are not helpful for those already sick. The long response time for vaccine creation and distribution is unsettling when a more lethal strain abruptly emerges and spreads rapidly. The speed of transmission is accelerated by the lack of widespread immunity in the general population to the latest form of the virus.
Flu trackers refer to strains by their H and N subtypes. H stands for hemagglutinins, which are the molecules on the flu virus that enable it to invade the cells of respiratory passages. The virus’s hemagglutinin molecules attach to the surface of cells lining the respiratory tract. When the cell tries to engulf the virus, it makes the error of pulling it into a more acidic location. The drop in pH changes the shape of the viral hemagglutinin, thereby allowing the virus to fuse to the cell and open an entry for the virus’ RNA to come in and start making fresh viruses. It is hypothesized that the Baker Lab protein inhibits this shape change by binding the hemagglutinin in a very specific orientation and thus keeps the virus from invading cells.
Dr. Baker and his team wanted to create antivirals that could react against a wide variety of H subtypes, as this versatility could lead to a comprehensive therapy for influenza. Specifically, viruses that have hemagglutinins of the H2 subtype are responsible for the deadly pandemic of 1957 and continued to circulate until 1968. People born after that date have not been exposed to H2 viruses. The recent avian flu has a new version of H1 hemagglutinin. Data suggest that Dr. Baker’s proteins bind to all types of the group I hemagglutinin, a group that includes not only H1 but also the pandemic H2 and avian H5 strains.
The methods developed for the influenza inhibitor protein design, according to Dr. Baker, could be “a powerful route to inhibitors or binders for any surface patch on any desired target of interest.” For example, if a new disease pathogen arises, scientists could figure out how it interacts with human cells or other hosts on a molecular level. Scientists could then employ protein interface design to create a diversity of small proteins that they predict would block the pathogen’s interaction surface.
Genes for large numbers of the most promising, computer-designed proteins could be tested using yeast cells. After additional molecular chemistry research to search for the best binding among those proteins, those could be reprogrammed in the laboratory to undergo mutations, and all the mutated forms could be stored in a “library” for an in-depth examination of their amino acids, molecular architecture, and energy bonds.
Sophisticated technologies would allow the scientists to rapidly browse through the library to find those tiny proteins that clung to the pathogen surface target with pinpoint accuracy. The finalists would be selected from this pool for excelling at blocking the pathogen from attaching to, entering, and infecting human or animal cells.
The utilization of deep sequencing, the same technology now used to sequence human genomes cheaply, was particularly central in creating detailed maps relating sequencing to function. These maps were used to reprogram the design to achieve a more exact interaction between the inhibitor protein and the virus molecule. It also enabled the scientists, they said, “to leapfrog over bottlenecks” to improve the activity of the binder. They were able to see how small contributions from many small alterations in the protein, too difficult to see individually, could together create a binder with better attachment strength.
“We anticipate that our approach combining computational design followed by comprehensive energy landscape mapping,” Dr. Baker said, “will be widely useful in generating high-affinity and high-specificity binders to a broad range of targets for use in therapeutics and diagnostics.”
Related Links:
University of Washington
“One of these engineered proteins has a flu-fighting potency that rivals that of several human monoclonal antibodies,” said Dr. David Baker, a professor of biochemistry at the University of Washington (Seattle, USA), in a report June 7, 2012, published in the journal Nature Biotechnology.
Dr. Baker’s research team is making major inroads in optimizing the function of computer-designed influenza inhibitors. These proteins are constructed via computer modeling to fit exquisitely into a specific nano-sized target on flu viruses. By binding the target areas similar to a key into a lock, they keep the virus from changing shape, a tactic that the virus uses to infect living cells. The research efforts, analogous to docking a space station but on a molecular level, are made possible by computers that can describe the panoramas of forces involved on the submicroscopic scale.
Dr. Baker is head of the new Institute for Protein Design Center at the University of Washington. Biochemists, engineers, computer scientists, and medical specialists at the center are engineering innovative proteins with new functions for specific purposes in medicine, environmental protection, and other areas. Proteins underlie all typical activities and structures of living cells, and also control disease actions of pathogens such as viruses. Abnormal protein formation and interactions are also implicated in many inherited and later-life chronic disorders.
Because influenza is a serious worldwide public health problem due to its genetic shifts and drifts that sporadically become more virulent, the flu is one of the key interests of the Institutes for Protein Design and its collaborators in the United States and worldwide. Researchers are trying to meet the vital need for better therapeutic agents to protect against this very adaptable and extremely infective virus. Vaccines for new strains of influenza take months to develop, evaluate, and manufacture, and are not helpful for those already sick. The long response time for vaccine creation and distribution is unsettling when a more lethal strain abruptly emerges and spreads rapidly. The speed of transmission is accelerated by the lack of widespread immunity in the general population to the latest form of the virus.
Flu trackers refer to strains by their H and N subtypes. H stands for hemagglutinins, which are the molecules on the flu virus that enable it to invade the cells of respiratory passages. The virus’s hemagglutinin molecules attach to the surface of cells lining the respiratory tract. When the cell tries to engulf the virus, it makes the error of pulling it into a more acidic location. The drop in pH changes the shape of the viral hemagglutinin, thereby allowing the virus to fuse to the cell and open an entry for the virus’ RNA to come in and start making fresh viruses. It is hypothesized that the Baker Lab protein inhibits this shape change by binding the hemagglutinin in a very specific orientation and thus keeps the virus from invading cells.
Dr. Baker and his team wanted to create antivirals that could react against a wide variety of H subtypes, as this versatility could lead to a comprehensive therapy for influenza. Specifically, viruses that have hemagglutinins of the H2 subtype are responsible for the deadly pandemic of 1957 and continued to circulate until 1968. People born after that date have not been exposed to H2 viruses. The recent avian flu has a new version of H1 hemagglutinin. Data suggest that Dr. Baker’s proteins bind to all types of the group I hemagglutinin, a group that includes not only H1 but also the pandemic H2 and avian H5 strains.
The methods developed for the influenza inhibitor protein design, according to Dr. Baker, could be “a powerful route to inhibitors or binders for any surface patch on any desired target of interest.” For example, if a new disease pathogen arises, scientists could figure out how it interacts with human cells or other hosts on a molecular level. Scientists could then employ protein interface design to create a diversity of small proteins that they predict would block the pathogen’s interaction surface.
Genes for large numbers of the most promising, computer-designed proteins could be tested using yeast cells. After additional molecular chemistry research to search for the best binding among those proteins, those could be reprogrammed in the laboratory to undergo mutations, and all the mutated forms could be stored in a “library” for an in-depth examination of their amino acids, molecular architecture, and energy bonds.
Sophisticated technologies would allow the scientists to rapidly browse through the library to find those tiny proteins that clung to the pathogen surface target with pinpoint accuracy. The finalists would be selected from this pool for excelling at blocking the pathogen from attaching to, entering, and infecting human or animal cells.
The utilization of deep sequencing, the same technology now used to sequence human genomes cheaply, was particularly central in creating detailed maps relating sequencing to function. These maps were used to reprogram the design to achieve a more exact interaction between the inhibitor protein and the virus molecule. It also enabled the scientists, they said, “to leapfrog over bottlenecks” to improve the activity of the binder. They were able to see how small contributions from many small alterations in the protein, too difficult to see individually, could together create a binder with better attachment strength.
“We anticipate that our approach combining computational design followed by comprehensive energy landscape mapping,” Dr. Baker said, “will be widely useful in generating high-affinity and high-specificity binders to a broad range of targets for use in therapeutics and diagnostics.”
Related Links:
University of Washington
Latest BioResearch News
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
Channels
Clinical Chemistry
view channel
AI Predicts Kidney Stone Composition From Routine Urine Tests
Kidney stones are a common and painful condition, affecting approximately one in 11 Americans, with lifetime recurrence rates of 60% to 80%. Identifying stone composition is important for guiding treatment... Read more
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read moreMolecular Diagnostics
view channelAMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







